Scandinavian ChemoTech receives approval from the US Patent Office
Scandinavian ChemoTech AB announces today that the Company has received approval from the US Patent Office for its innovation for the treatment of pain caused by metastases in the spine and skeleton. This innovation is also applicable to the treatment of deep-seated tumours, which is another of the Company's development projects.
The patent is based on the same innovation that was approved in Europe in July 2021 and includes a specially developed electrode as well as unique dynamic properties. These functions are already implemented in the TSE platform and are intended to treat tumours without damaging important parts of organs and tissues, such as nerve pathways and blood vessels. This is of utmost importance in the treatment of, among other things, the spine and organs such as the pancreas.
“This patent creates increased protection for the Company's innovations also in the USA, an extremely interesting market for two of ChemoTech's most important development projects.” - says Mohan Frick, CEO and author to this patent along with Prof B Persson
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.